Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | PHASE3 | ACTIVE NOT_RECRUITING | 95 | — | — | Jun 15, 2022 | Sep 23, 2026 | Jun 8, 2026 | 52 | United States, Argentina +23 |
PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on central assessment and using RECIST 1.1 criteria.
| Arm | Type | Description |
|---|---|---|
| JDQ443 | EXPERIMENTAL | Participants will be treated with JDQ443 |
| Docetaxel | ACTIVE_COMPARATOR | Participant will be treated with docetaxel following local guidelines as per standard of care and product labels |
| Name | Type | Description |
|---|---|---|
| JDQ443 | DRUG | JDQ443 tablets, orally administered |
| docetaxel | DRUG | docetaxel concentrated solution for infusion, intravenously administered |
Inclusion Criteria: * Participant has histologically confirmed locally advanced/metastatic (stage IIIB/IIIC or IV) * Participant has a KRAS G12C mutation present in tumor tissue or plasma prior to enrollment, as determined by a Novartis designated central laboratory or by accepted local tests. * Pa...